Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease

Abstract Introduction This study examined plasma glial fibrillary acidic protein (GFAP) as a biomarker of cognitive impairment due to Alzheimer's disease (AD) with and against plasma neurofilament light chain (NfL), and phosphorylated tau (p‐tau)181+231. Methods Plasma samples were analyzed usi...

Full description

Bibliographic Details
Main Authors: Madeline Ally, Michael A. Sugarman, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Thomas K. Karikari, Hugo J. Aparicio, Brandon Frank, Yorghos Tripodis, Brett Martin, Joseph N. Palmisano, Eric G. Steinberg, Irene Simkin, Lindsay A. Farrer, Gyungah R. Jun, Katherine W. Turk, Andrew E. Budson, Maureen K. O'Connor, Rhoda Au, Lee E. Goldstein, Neil W. Kowall, Ronald Killiany, Robert A. Stern, Thor D. Stein, Ann C. McKee, Wei Qiao Qiu, Jesse Mez, Michael L. Alosco
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Alzheimer's disease
glial fibrillary acidic protein
neuropsychology
neurofilament light chain
phosphorylated tau
plasma biomarkers
Online Access:https://doi.org/10.1002/dad2.12492

Internet

https://doi.org/10.1002/dad2.12492

Similar Items